To test this hypothesis, we analyzed metabolomics data from the CCLE database including measurements of 225 metabolite levels in 928 cell lines from more than 20 cancer types (35) and compared metabolite levels between cells with DDX1-MYCN coamplification to those only harboring MYCN amplification. This evidence concerns the gene MYCN and cancer.